Phase 3 Data Put Povorcitinib on HS Radar – Medscape

  1. Phase 3 Data Put Povorcitinib on HS Radar  Medscape
  2. Incyte stock rating reiterated by Citizens JMP amid promising drug data  Investing.com
  3. INCY Announces New Late-Stage Data on Skin Disease Drug  Yahoo Finance
  4. Povorcitinib Improves Moderate to Severe Hidradenitis Suppurativa at Week 24  HCPLive
  5. Incyte’s Povorcitinib Wins Stack Up, Will It Be Enough To Hedge Jakafi Loss?  insights.citeline.com

Continue Reading